(The Conversation is an independent, non-profit source of news, analysis, and observation from education experts. )
(THE CONVERSATION) Imagine only inhaling a few drops of liquid or fog to protect yourself from COVID-19. This is the concept of nasal vaccines against COVID-19, and recently they have attracted a lot of attention in the form of an aerosol or liquid. These nasal vaccines would be based on the same generation as general vaccines given by injection. But as Mayuresh Abhyankar, a researcher at the University of Virginia who studies infectious diseases and works on nasal vaccines, explains, vaccinating someone where the coronavirus is most likely to start their attack has many immune benefits.
Nasal vaccines are given, as the call suggests, through the nose. Specifically, the so-called intranasal vaccines, these vaccines are liquids that can be administered in the form of an aerosol or through a dropper or syringe. The most common nasal vaccine is FluMist, a nasal spray. that uses the inactivated flu virus to oppose the flu. An intranasal vaccine may simply be a weakened live virus similar to FluMist, a nucleic acid vaccine such as mRNA coronavirus vaccines, or a protein vaccine such as hepatitis B vaccines or the corbeVax coronavirus vaccine.
Intranasal vaccines are most effective against pathogens that enter through the nose, such as the flu or coronavirus. By mimicking the first level of natural exposure to an airborne pathogen, these vaccines help exercise the user’s immune formula at the possible location of the infection. Scientists have shown that the first immune reaction in the respiratory tract after a user is exposed to a virus in the air can influence how the user gets sick. Therefore, in theory, intranasal vaccines can offer more ions than vaccines given by injection into the arm.
SARS-CoV-2, the virus that causes COVID-19, enters the frame through the nose and lands on the mucous membrane at the back of the nostrils and throat. The virus then enters the cells it touches, replicates, and spreads. .
Just below those mucous membrane cells are many types of immune cells that shape what is called the mucosal immune formula. Cells of the mucosal immune formula are the first to identify invasive coronavirus remnants and begin to expand a protective response.
In an unvaccinated person, those immune cells take about two weeks to spread a reaction after encountering the coronavirus. By this time, the virus may have seamlessly inflamed other parts of the body, such as the lungs, which can lead to serious illness. .
Nasal vaccines follow largely the same steps. When you inhale a nasal vaccine, waste falls into the mucous membrane of the nasal hollow space or into the back of the throat, the cells enter those places, and provoke an immune response. This procedure informs the framework about the coronavirus and allows it to cope with any genuine infection in the long term.
When you receive an injection of COVID-19 into your arm, the vaccine triggers a strong immune reaction in the cells near where you received the injection. It also motivates its immune formula to produce specific antibodies against the coronavirus and other immune cells elsewhere. your body.
When the coronavirus begins to infect a person’s airway cells, nearby immune cells will begin to build a defense. Your frame will also send antiviral immune cells and antibodies from elsewhere to the site of infection. But over time, enough coronavirus-specific immune cells gather around the site of infection to prevent the virus from replicating, most likely the virus has already begun to spread the frame, making it difficult to maintain the immune system.
Nasal vaccines mimic the virus to prepare the immune formula against a virus, just like any other vaccine. But most importantly, they also mimic the infection process and the protective reaction within the mucous immune formula of the nose and throat. Simply put, intranasal vaccinations are like knowing there’s going to be a break-in and putting guards in the right position before the discomfort starts.
Science confirms this idea. In a direct comparison, AstraZeneca’s COVID-19 vaccine provided greater coverage in intranasally vaccinated hamsters than intramuscularly vaccinated.
Nasal vaccination can also be used in conjunction with intramuscular immunization. In a recent study, my colleagues and I gave some mice a nasal and intramuscular vaccine and exposed them to a deadly dose of SARS-CoV-2, one hundred percent of those combined. vaccinated mice survived, compared to only 10% of unvaccinated mice. Lately we are testing whether this combined technique is better than intranasal or intramuscular techniques alone.
Finally, intranasal vaccines are painless, non-invasive, and require specialized education for their use.
Getting the right dose can be more complicated with nasal vaccines than with an injection, especially in young children. If you have a stuffy nose or sneeze at the vaccine component before it is fully absorbed, this could result in a lower dose than the desired dose. .
There are also exclusive fitness risks. All vaccines go through rigorous protective testing and clinical trials, but those processes are especially vital for nasal vaccines because of the undeniable fact that the nose is close to the brain. Switzerland developed a brief facial paralysis, also known as Bell’s palsy. Later, the researchers discovered that a bacterial toxin added to the vaccine for the immune reaction was to blame.
This is the reported case of neurological disorders resulting from intranasal vaccines, but it is something to keep in mind.
As of the end of May 2022, there are no intranasal COVID-19 vaccines approved for human use. Lately there are seven in clinical trials and three of them, manufactured by Beijing Wantai Biological Pharmacy, Bharat Biotech and Codagenix and Serum Institute of India. – are in phase 3 human trials.
In the coming months, the effects of those trials will show not only what those promising new vaccines look like, but also whether they work better than the vaccines used today.
This article is republished from The Conversation under a Creative Commons license. Read the original article here: https://theconversation. com/nasal-covid-19-vaccines-help-the-body-prepare-for-infection-right-where-begins-in-your-nose-and-gorge-183790.